 |
|
Efficacy of Topical 5% Imiquimod Cream for the Treatment of Nodular Basal Cell Carcinoma
Comparison of Dosing Regimens
Stephen Shumack, FACD;
June Robinson, MD;
Steven Kossard, FACD;
Loren Golitz, MD;
Hubert Greenway, MD;
Arnold Schroeter, MD;
Kara Andres, MS;
Mark Amies, MBBS;
Mary Owens, MD
Arch Dermatol. 2002;138:1165-1171.
Objective To establish a safe and efficacious dosing regimen for the treatment of primary nodular basal cell carcinoma (BCC) using 5% imiquimod cream.
Design Two phase 2 studies were conducted: a 6-week, randomized, open-label, dose-response study evaluating 4 dosing regimens and a 12-week, randomized, vehicle-controlled, double-blind, dose-response study evaluating 4 dosing regimens.
Setting Twenty-four public and private dermatology clinics in Australia and New Zealand (6-week study) and the United States (12-week study) participated.
Patients The study populations comprised 99 patients enrolled in the 6-week study and 92 patients in the 12-week study. Patients were at least 18 years old and had a biopsy-confirmed diagnosis of nodular BCC.
Interventions In the 6-week study, imiquimod was applied once daily for 3 or 7 days per week or twice daily for 3 or 7 days per week. In the 12-week study, imiquimod or placebo cream (vehicle) was applied once daily for 3, 5, or 7 days per week, or twice daily for 7 days per week. The entire tumor area was excised 6 weeks after treatment and examined histologically for evidence of remaining BCC.
Main Outcome Measure The proportion of patients having no histologic evidence of BCC in the posttreatment excision specimen.
Results Dosing once daily for 7 days per week resulted in the highest clearance rate, with 25 (71%) of 35 and 16 (76%) of 21 patients showing clearance of their tumor in the 6- and 12-week studies, respectively.
Conclusions Topical 5% imiquimod cream is well tolerated and most effective in treating nodular BCC when applied once daily for 7 days per week for either 12 or 6 weeks.
From the St George Hospital, Kogarah, Australia (Dr Shumack); Loyola University Medical Center, Maywood, Ill (Dr Robinson); the Skin and Cancer Foundation Australia, Darlinghurst (Dr Kossard); Dermatopathology Services, LLC, Denver, Colo (Dr Golitz); the Scripps Clinic, La Jolla, Calif (Dr Greenway); the Mayo Clinic, Rochester, Minn (Dr Schroeter); 3M Pharmaceuticals, St Paul, Minn (Ms Andres and Dr Owens); and 3M Health Care, Thornleigh, (Dr Amies).
RELATED LETTER
Fifty-five Basal Cell Carcinomas Treated With Topical Imiquimod: Outcome at 5-Year Follow-up
David Vidal, Xavier Matías-Guiu, and Agustín Alomar
Arch Dermatol. 2007;143(2):266-268.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Fifty-five Basal Cell Carcinomas Treated With Topical Imiquimod: Outcome at 5-Year Follow-up
Vidal et al.
Arch Dermatol 2007;143:266-268.
FULL TEXT
Basal-Cell Carcinoma.
Rubin et al.
NEJM 2005;353:2262-2269.
FULL TEXT
Interventions for basal cell carcinoma of the skin: systematic review
Bath-Hextall et al.
BMJ 2004;329:705.
ABSTRACT
| FULL TEXT
Keratinocyte Carcinoma
Albert and Weinstock
CA Cancer J Clin 2003;53:292-302.
ABSTRACT
| FULL TEXT
Imiquimod for Basal Cell Carcinoma: Act II
Journal Watch Dermatology 2002;2002:6-6.
FULL TEXT
|
